The inability of the heart to efficiently relax as it beats, termed diastolic dysfunction, is a major underlying cause of heart disease. As a new strategy for treating diastolic dysfunction, Joseph Metzger and his colleagues engineered directed substitutions in the calcium-binding protein Parvalbumin to optimize its ability to promote cardiac myocyte relaxation. Gene transfer of this Parvalbumin variant promoted cardiac myocyte relaxation of rabbit and canine heart failure models in vitro and corrected heart function in two in vivo mouse models of diastolic dysfunction.
- Wang Wang
- Matthew S Barnabei
- Joseph M Metzger